OMTX-705 is under clinical development by Oncomatryx Biopharma and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OMTX-705’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OMTX-705 overview
OMTX-705 is under development for the treatment of solid tumor, pancreatic ductal adenocarcinoma, gastric cancer, head and neck cancer squamous cell carcinoma, esophageal cancer, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, leiomyosarcoma and triple-negative breast cancer. The drug candidate is developed by drug design technology in which a monoclonal antibody (anti-MTX5) is conjugated to cytolysin. It targets cells expressing fibroblast activation protein (FAP).
Oncomatryx Biopharma overview
Oncomatryx Biopharma (Oncomatryx) is a company that discovers novel stromal biomarkers for accurate diagnosis and prognosis of invasive tumors. The company provides precision drugs that target proteins located in the tumor environment. It develops therapeutic antibody-drug conjugates that target proteins located in the tumor microenvironment. The company’s pipeline products include OMTX705 which targets pancreatic cancer, lung, breast and ovarian cancer; OMTX703 which treats ewing sacroma, uveal melanoma, nervous sacroma and malignant peripheral nerve sheath tumor (MPNST). It markets its products through a network of distributors in Spain and abroad. Oncomatryx is headquartered in Derio, Spain.
For a complete picture of OMTX-705’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
